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Background: Neuroinﬂammation and white matter pathology have each been independently associated with
schizophrenia, and experimental studies have revealed mechanisms by which the two can interact in vitro, but
whether these abnormalities simultaneously co-occur in people with schizophrenia remains unclear.
Method:We searchedMEDLINE, EMBASE, PsycINFO andWeb of Science from inception through 12 January 2014
for studies reporting human data on the relationship betweenmicroglial or astroglial activation, or cytokines and
white matter pathology in schizophrenia.
Results: Fifteen studies totaling 792 subjects (350 with schizophrenia, 346 controls, 49 with bipolar disorder, 37
with major depressive disorder and 10 with Alzheimer's disease) met all eligibility criteria. Five neuropatholog-
ical and twoneuroimaging studies collectively yielded consistent evidence of an association between schizophre-
nia and microglial activation, particularly in white rather than gray matter regions. Ultrastructural analysis
revealed activated microglia near dystrophic and apoptotic oligodendroglia, demyelinating and dysmyelinating
axons and swollen and vacuolated astroglia in subjects with schizophrenia but not controls. Two neuroimaging
studies found an association between carrier status for a functional single nucleotide polymorphism in the
interleukin-1β gene and abnormalwhite aswell as graymatter volumes in schizophrenia but not controls. A neu-
ropathological study found that orbitofrontal white matter neuronal density was increased in schizophrenia
cases exhibiting high transcription levels of pro-inﬂammatory cytokines relative to those exhibiting low tran-
scription levels and to controls. Schizophrenia was associated with decreased astroglial density speciﬁcally in
subgenual cingulate white matter and anterior corpus callosum, but not other gray or white matter areas.
Astrogliosis was consistently absent. Data on astroglial gene expression, mRNA expression and protein concen-
tration were inconsistent.
Conclusion: Neuroinﬂammation is associated with white matter pathology in people with schizophrenia, and
may contribute to structural and functional disconnectivity, even at the ﬁrst episode of psychosis.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Schizophrenia is a severe neuropsychiatric disorder that represents
the 18th leading cause of years lived with disability globally (Whiteford
et al., 2013) and has an estimated point prevalence of 0.5% to 1.0%
(Tandon et al., 2008). Functional and structural disconnectivity are
among themost reproducible neurophysiological abnormalities associat-
ed with schizophrenia (Burns et al., 2003; Whalley et al., 2005; Liang
et al., 2006; Begre and Koenig, 2008; Konrad and Winterer, 2008;n, Department of Neurology,
ork, NY 10016, United States.
. This is an open access article under tHoptman et al., 2010; Qiu et al., 2010; Whitford et al., 2011; Shi et al.,
2012a,b; Curčić-Blake et al., 2013; Rane et al., 2013; Straube et al.,
2013; Tepest et al., 2013) (recently reviewed by Schmitt et al. (2011)).
Structural connectivity refers tomacroscopic neuroanatomical dynamics,
and is commonly measured by diffusion-tensor imaging (DTI)
tractography, volumetric magnetic resonance imaging (MRI) and
magnetization-transfer imaging. Functional connectivity refers to the
temporal correlation between neuronal activity in two or more
neuroanatomically distinct regions, and is commonly measured by func-
tionalMRI (Greicius et al., 2009; Honey et al., 2009). There are several re-
cent systematic reviews on the evidence for structural disconnectivity in
schizophrenia (Di et al., 2009; Bora et al., 2011; Olabi et al., 2011; Patel
et al., 2011; De Peri et al., 2012; Kuswanto et al., 2012; Haijma et al.,
2013; Samartzis et al., 2014; Yao et al., 2013). In the most inclusive of
these, which focused on DTI studies, the authors found consistent evi-
dence of white matter pathology affecting frontal, fronto-temporal andhe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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lum bundle, uncinate fasciculus and corpus callosum (Samartzis et al.,
2014), which they and others have provided evidence to suggest, are
changes thatmaybe evident duringﬁrst-episode presentations of schizo-
phrenia (Downhill et al., 2000; Bachmann et al., 2003; Innocenti et al.,
2003; Li et al., 2014; Reis Marques et al., 2014; Samartzis et al., 2014).
White matter pathology of oligodendroglia and myelinated ﬁbers is
thought to represent the neurobiological basis of structural and function-
al disconnectivity in schizophrenia (Davis et al., 2003). Oligodendroglial
pathology documented in schizophrenia includes morphological abnor-
malities in prefrontal cortex (Uranova et al., 2001, 2011) and reduced
cellular density, particularly in the prefrontal cortex, anterior cingu-
late cortex and hippocampus (Uranova et al., 2002; Davis et al., 2003;
Hof et al., 2003; Uranova, 2004; Uranova et al., 2004; Vostrikov et al.,
2004; Helldin et al., 2007; Mitelman et al., 2007a,b; Friedman et al.,
2008a,b; Borgwardt et al., 2009a,b; Williams et al., 2013, 2014). Mi-
croarray messenger RNA (mRNA) expression studies and single-cell
gene quantitative real-time polymerase chain reaction (PCR) studies
have documented reduced expression of several oligodendroglial- and
myelin-associated proteins in schizophrenia, such as 2′, 3′-cyclic nucleo-
tide 3′-phosphodiesterase (CNP), myelin basic protein, myelin-
associated glycoprotein (MAG), myelin and lymphocyte protein, gelsolin,
transferrin and ErbB3 (Hakak et al., 2001; Davis et al., 2003; Flynn et al.,
2003; Tkachev et al., 2003). A single nucleotide polymorphism in the
Olig2 gene that is necessary for maturation of oligodendroglial lineage
has been associated with reduced white matter fractional anisotropy
(FA) in schizophrenia (Prata et al., 2012). Progressive white matter vol-
ume loss has also been documented in schizophrenia (Olabi et al., 2011;
Haijma et al., 2013), and positively correlateswith the severity of negative
symptoms, impulsivity and aggression (Sanﬁlipo et al., 2000;Wible et al.,
2001a,b; Hoptman et al., 2002; Wolkin et al., 2003; Uranova et al., 2011).
In certain neurodevelopmental disorders, like periventricular
leukomalacia, an insult to the developing brain results in
neuroinﬂammation-mediated injury to oligodendroglial progeni-
tor cells, which in turn leads to white matter pathology and
disconnectivity abnormalities resembling those found in schizophrenia
(Rousset et al., 2006; Leviton and Gressens, 2007). A separate line of in-
vestigation documents a robust association between neuroinﬂamma-
tion and schizophrenia (Bayer et al., 1999; Radewicz et al., 2000;
Wierzba-Bobrowicz et al., 2005; Steiner et al., 2006; Steiner et al.,
2008; van Berckel et al., 2008; Doorduin et al., 2009; Monji et al.,
2009; Miller et al., 2011; Van Berckel et al., 2011; Van Der Doef et al.,
2011; Fillman et al., 2013; Miller et al., 2013b) (recently reviewed by
our group (Najjar et al., 2013)). Neuroinﬂammation is characterized
by a complex cascade involvingmicroglial activation, upregulated cyto-
kine signaling, and/or astroglial loss and activation that persist beyond a
transient neuroprotective phase normally down-regulated by feedback
mechanisms, thereby establishing a progressive pathological state that
promotes further neuronal injury (Streit et al., 2004; Najjar et al.,
2013). Neuroinﬂammatory mechanisms implicated in schizophrenia,
include glial (astroglial loss and activation, microglial activation and
priming), immunologic (cytokines, chemokines, prostaglandins) and
oxidative (reactive oxygen and nitrogen species) aberrations. These
mechanisms are thought to result in glutamatergic (hypofunction)
and dopaminergic (limbic hyperfunction, frontal hypofunction)
dysregulation by various putative pathways, such as increasing astroglial
synthesis of kynurenic acid (an N-methyl-D-aspartate receptor and α-7-
nicotinic acetylcholine receptor antagonist) and S100β, and upregulating
excitatory amino acid transporter expression (Najjar et al., 2013).
Only recently, however, as evidence supporting the importance of
neuroinﬂammation in the pathophysiology of schizophrenia has accu-
mulated over the last decade, have researchers begun directly investi-
gating how neuroinﬂammation might link neurodevelopmental
abnormalities to progressive white matter pathology/disconnectivity
in schizophrenia (Chew et al., 2013; Monji et al., 2013). To date, there
has been no systematic attempt to synthesize and analyze data to thiseffect. As such, and given the variety of sub-disciplines contributing to
this work, both the nature and quality of this evidence viewed in aggre-
gate aswell as the relative reproducibility of its composite ﬁndings indi-
vidually, remain unclear. Here, we aimed to characterize the extant
literature relating neuroinﬂammation to white matter pathology in
schizophrenia by performing a systematic reviewof humandata derived
from neuropathological and neuroimaging studies.
2. Material and methods
2.1. Search strategy
We performed a systematic electronic search for records indexed
within MEDLINE, EMBASE, PsycINFO or Web of Science from inception
through 12 January 2014 to identify potentially eligible studies; see
Table S1 in the Supplementary Appendix for a copy of our full-length
search strategy. We sought both published (peer-reviewed journal
articles) and unpublished (meeting abstracts) data sources. We supple-
mented these electronic searches by manually reviewing the reference
lists of eligible studies.
2.2. Study selection
After removing duplicates from the set of records retrieved by these
searches, we selected studies for inclusion based on the following eligi-
bility criteria: (a) neuropathological or neuroimaging studies that pro-
vided data on both (b) neuroinﬂammation and (c) white matter
pathology (d) in individuals with schizophrenia. Regarding the neuro-
inﬂammation criterion, we focused our analysis on studies providing
data onmicroglia, cytokines and/or astroglia, because abnormalities in-
volving these cells and signaling molecules represent the central ele-
ments of neuroinﬂammation (Streit et al., 2004). To avoid introducing
bias in comparisons of gray and white matter pathology across different
populations, disease states and other potential confounders, we excluded
studies that reported data on neuroinﬂammation-related outcomes in
gray but not white matter.
2.3. Data extraction and synthesis
We extracted data onto a standardized and piloted data collection
form maintained on an electronic spreadsheet (available from the au-
thors by request). For characteristics of included studies and subjects,
we extracted data on citation information, eligibility criteria, publication
type, study type, age and sex of subjects and duration of illness. We ex-
tracted data on all outcome measures related to neuroinﬂammation in
white and gray matter in individuals with schizophrenia and compari-
son groups.We extracted data on neuroinﬂammation-related outcomes
for a given Brodmann Area or next most-speciﬁc neuroanatomical re-
gion provided. We preserved any existing distinctions regarding white
versus gray matter, left versus right hemispheres and males versus fe-
males. We summarized comparisons between schizophrenia versus
control subjects on continuous and categorical outcome measures as
themean difference with 95% conﬁdence intervals (CIs) and odds ratios
with 95% CIs, respectively, using the RevMan statistical software pack-
age (Review Manager version 5.2, Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2012).
3. Results
3.1. Search results
Fig. 1 summarizes the results of the search strategy and study selec-
tion processes. Fifteen studies described across 18 reports (14 journal
articles and four meeting abstracts) met all eligibility criteria (see
Table 1). Three studies were described across two reports each: (a)
(Fillman et al., 2013; Fung et al., 2014), (b) (Beasley and Hercher,
747 Total records identified by systematic 
electronic database searches
137 MEDLINE (1946–W3 Nov 2013)
196 EMBASE (1974–10 Jan 2014)
69 PsycINFO (1808–W1 Jan 2014)
345 Web of Science (1990–12 Jan 2014)
350 Records excluded after 
screening titles and abstracts
396 Unique records screened after removing 
duplicate records
31 Studies excluded with reasons
24 Not neuroinflammation
6 Not white matter
1 Missing outcome data
46 Full-texts assessed for eligibility
15 Studies (18 records) included for qualitative 
synthesis in the systematic review
Fig. 1. Study ﬂow diagram.
104 S. Najjar, D.M. Pearlman / Schizophrenia Research 161 (2015) 102–1122011, 2013) and (c) (Williams et al., 2014; Williams et al., 2013). There
were 792 total subjects (see Table S2 in the Supplementary Appendix),
including 350 subjects with schizophrenia (mean ± standard deviation:
age, 48 ± 18 years; male sex, 66% ± 27%; duration of illness, 16 ±
10 years) and 346 controls (mean ± standard deviation: age, 46 ±
16 years; male sex, 65% ± 19%). The remaining subjects consisted of
49 with bipolar disorder, 37 with major depressive disorder and 10
with Alzheimer's disease.
3.2. Microglia
Five neuropathological studies and two neuroimaging studies (222
subjects) yielded data onmicroglial activation inwhitematter brain tis-
sue in schizophrenia (see Table 2). One neuropathological study
assessed microglial density in the dorsolateral prefrontal gray and
white matter and found a signiﬁcantly increased density of major histo-
compatibility class II (MHC-II) human leukocyte antigen (HLA)-DR-im-
munoreactive dorsolateral prefrontal white matter microglia in
subjects with schizophrenia compared with controls (Fillman et al.,
2013). Another neuropathological study assessed dorsolateral pre-
frontal, superior temporal, and anterior cingulate gray and white
matter. HLA-immunoreactive dorsolateral prefrontal and superior
temporal gray and white matter microglial density was signiﬁcantly
increased in those with schizophrenia; this pattern approached sta-
tistical signiﬁcance in anterior cingulate gray and white matter
(Radewicz et al., 2000). Both of these studies found increased HLA-
immunoreactive microglia l density in white relative to gray matter
among those with schizophrenia. A third study reported no signiﬁ-
cant difference in the density of ionized calcium-binding adaptermolecule 1 protein (IBA1)-immunoreactive prefrontal white matter
microglia among subjects with schizophrenia relative to controls
(Beasley and Hercher, 2013). A fourth study found HLA-DR-immunore-
active prefrontal gray and white matter microglial activation in 3 of 14
subjects with schizophrenia (1 with microgliosis), 4 of 8 subjects with
Alzheimer's disease (4withmicrogliosis), 1 of 13 subjectswith affective
disorder (1 with microgliosis), and 0 of 13 controls. All three subjects
with schizophrenia andmicroglial activation had late-onset schizophre-
nia at 40, 46, and 50 years of age. Microglial density was not quantiﬁed
in this study (Bayer et al., 1999).
Ultrastructural analyses from an electronmicroscopy study revealed
activated microglia that contained myelin membranous debris located
between myelin sheath lamellae and adjacent to swollen and vacuolat-
ed astroglia, in prefrontal white matter specimens of subjects with
schizophrenia but not in those of controls (Uranova et al., 2011).
Microglial-like cells were also detected betweenmyelin sheath lamellae
in gray matter sections. Oligodendroglia were either dystrophic (cyto-
plasmic swelling and vacuolation) in gray and white matter, or apopto-
tic/necrotic (nuclear chromatin clumping, pyknotic nuclei, and lysis of
organelle membranes) in gray matter alone. Several patterns myelinat-
ed ﬁber abnormalitieswere also identiﬁed. Thesewere characterized ei-
ther by demyelination (focal lysis and disrupted compaction of myelin
sheath lamellae often with formation of concentric lamellar bodies),
dysmyelination or axonal degeneration.
One positron emission tomography study evaluated the binding po-
tential of (R)-N-11C-methyl-N-(1-methylpropyl)-1-(2-chlorophenyl)-
isoquinoline-3-carboxamide ((R)-11C-PK11195), which is a peripheral
benzodiazepine receptor ligand somewhat speciﬁc formicroglial activa-
tion. Whole-brain gray and white matter binding potentials were 30%
and 20% higher, respectively, in those with schizophrenia compared
with controls. Binding potential was also signiﬁcantly increased in hip-
pocampal combined gray and white matter among those with schizo-
phrenia (Doorduin et al., 2009). Another neuroimaging study used a
novel DTI approach that distinguishes between extracellular free-
water volume—indicative of neuroinﬂammation (Wang et al., 2011),
and tissue-speciﬁc fractional anisotropy (FAT)—reﬂecting axonal degen-
eration (Pasternak et al., 2009), the sum of which is equal to the value
of FA asmeasured by conventional DTI studies. Among thosewith schizo-
phrenia, extracellular free-water volume was signiﬁcantly increased
throughout gray and white matter, whereas FAT was signiﬁcantly de-
creased speciﬁcally in the superior longitudinal fasciculus bilaterally, the
right inferior frontal occipital fasciculus, and the intersection of callosal
ﬁbers with the right superior corona radiata (Pasternak et al., 2012).
3.3. Cytokines
Twoneuropathological studies and three neuroimaging studies (349
subjects) yielded data on the relationship between cytokines and white
matter pathology (see Table 3). One study found a signiﬁcant positive
correlation between microglial density and interleukin-1β (IL-1β)
mRNA expression in the dorsolateral prefrontal white – but not gray –
matter among schizophrenia subjects (Fillman et al., 2013). In a
follow-up analysis, the density of neuronal nuclear antigen (NeuN)-im-
munoreactive orbitofrontal white matter neurons was almost 50%
higher in schizophrenia subjects with high transcription levels of inter-
leukin (IL)-6, IL-8, IL-1β, and serpin peptidase inhibitor, clade A (α-1
antiproteinase, antitrypsin) and member 3 (SERPINA3) (henceforth
“high-inﬂammation subgroup”) comparedwith controls. Signiﬁcant dif-
ferences were also observed in the density of NeuN-immunoreactive
dorsolateral prefrontal white matter neurons (18.9% higher in the
high-inﬂammation subgroup compared with controls), and the density
of NeuN-immunoreactive orbitofrontal, but not dorsolateral prefrontal,
white matter neurons (14.9% higher in the low-inﬂammation sub-
group compared with controls, and 25.0% higher in the high-
inﬂammation subgroup compared with the low-inﬂammation
subgroup). The density of glutamic acid decarboxylase 65/67 kDa
Table 1
Included studies reporting on the relationship between neuroinﬂammation and white matter pathology in individuals with schizophrenia.
SCZ CTR PMID Methods Gray matter White matter Main outcome measures
Microglia
Fillman et al., 2013 37 37 22869038 Histology BA46 BA46 Microglial density (HLA-DR)
Beasley and Hercher, 2013 20 20 23821786 Histology PFC PFC Microglial density (IBA-1)
Radewicz et al., 2000 8 10 10749103 Histology BA9, 22, 24 BA9, 22, 24 Microglial density (HLA-DR)
Uranova et al., 2011 12 12 22937264 Histology BA10 (layer V) BA10 Microglial, oligodendroglial, myelin sheath ultrastructure (electronmicroscopy)
Bayer et al., 1999 14 13 10477118 Histology Hipp, PFC Hipp, PF Activation (HLA-DR)
Doorduin et al., 2009 7 8 19837763 PET Whole-brain d Whole-brain d Activation (11C-(R)-PK11195 binding potential)
Pasternak et al., 2012 18 20 23197727 DTIFW b Whole-brain Whole-brain Volume (extracellular free-water), tissue-speciﬁc fractional anisotropy (FAT) c
Cytokines
Fung et al., 2014 37 37 23830667 Histology – BA11, 46 Neuronal density (NeuN, GAD65/67), by mRNA: IL-6, IL-8, IL-1β, SERPINA3
Fillman et al., 2013 37 37 22869038 Histology BA46 BA46 mRNA: IL-6, IL-8, IL-1β, and SERPINA3
Maitra et al., 2009 61 54 19760350 MRI Whole-brain Whole-brain Gray and white matter volume, by IL-1β functional SNP allele 2 risk carriers
Meisenzahl et al., 2001 44 48 11481169 MRI Whole-brain Whole-brain Gray and white matter volume, by IL-1β functional SNP allele 2 risk carriers
Prasad et al., 2013 39 29 23821786 DTI Whole-brain Whole-brain Fractional anisotropy, mean diffusivity, by IL-6 and C-reactive protein
Astroglia
Williams et al., 2013, 2014 10 20 22660922 Histology BA25 BA25, CC Astroglial density (GFAP), oligodendroglial density
Williams et al., 2013 10 20 24374936 Histology BA25 BA25 Astroglial density (ﬁbrillary vs. gemistocytic)
Beasley and Hercher, 2011 20 20 21513031 Histology – Superﬁcial PF Astroglial density (GFAP), oligodendroglial density
Radewicz et al., 2000 8 10 10749103 Histology BA9, 22, 24 BA9, 22, 24 Astroglial density (GFAP)
Falkai et al., 1999 33 26 10194775 Histology BA28, 48 BA6, 3rd V, IH Astroglial density (GFAP)
Uranova et al., 2011 12 12 22937264 Histology BA10 BA10 Astroglial, oligodendroglial, myelin sheath ultrastructure (electron microscopy)
Katsel et al., 2011 18 21 21270770 Histology BA24 BA24 mRNA: DIO, AQP4, ALDH1L1, S100β, GFAP, VIM, THBS4, GS, EAAT-2, GL
Beasley et al., 2009 15 13 19272755 Histology – Internal capsule GFAP protein concentration
Barley et al., 2009 14 13 19447584 Histology Thal, putamen Internal capsule Astroglial (ALDH1L1, GFAP) and oligodendroglial gene expression a
ADAM12, A disintegrin and metalloprotease; AQP4, aquaporin-4; ALDH1L1, aldehyde dehydrogenase 1 familymember L1; BA, Brodmann area; BA6, premotor cortex and supplementary
motor area; BA9, dorsolateral prefrontal cortex; BA11, orbitofrontal cortex; BA22, superior temporal gyrus; BA28, entorhinal cortex; BA24, anterior cingulate; BA25, subgenual cingulate;
BA48, subiculum; CC, corpus callosum; CTR, control; DIO, diodinase type II; EAAT2, excitatory amino-acid transporter 2; EM, electronmicroscopy; FA, fractional anisotropy; FAT, fractional
anisotropy in tissue; FW, free-water; GAD, glutamic acid decarboxylase; GL, glutaminase; GFAP, glial ﬁbrillary acidic protein; GS, glutamine synthase; Hipp, hippocampus; HLA-DR, human
leukocyte antigen DR; IH, inferior horn; IL, interleukin; PMID, PubMed Identiﬁer; PET, positron emission tomography; PF, prefrontal region; PFC, prefrontal cortex; (R)-[11C]-PK11195,
isoquinoline (R)-N-11C-methyl-N-(1-methylpropyl)-1-(2-chlorophenyl)-isoquinoline-3-carboxamide; SCZ, schizophrenia; Thal, thalami; THBS4, thrombospondin; VIM, vimentin; 3rd
V, 3rd ventricle subventricular zone.
a NG2, PDGFRα, SOX11, SOX10, OLIG2, FYN, TF CNP, GALC, GTX, MAG, MAL, MOG, MOBP and PLP1.
b Diffusion-tensor imaging with free-water extracellular ﬂuid volume measurement as a marker neuroinﬂammation (see Pasternak et al., 2012).
c Fractional anisotropy in tissue equal to [conventional] fractional anisotropy less free-water extracellular ﬂuid volume.
d Gray and white matter; frontal, occipital, temporal and parietal cortices; basal ganglia, thalamus, hippocampus, midbrain, cerebellum and pons.
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frontal, white matter neurons was also signiﬁcantly higher in both
high-inﬂammation and low-inﬂammation subgroups compared with
controls; however, there was no statistically signiﬁcant difference be-
tween the high-inﬂammation and low-inﬂammation subgroups.
Among the high-inﬂammation subgroup, a signiﬁcant negative correla-
tionwas also observed between the densities of NeuN-immunoreactive
white matter neurons and GAD67-immunoreactive gray matter neu-
rons in the dorsolateral prefrontal region (Fung et al., 2014).
Two studies assessed gray and white matter volumes of schizophre-
nia and control participants in relation to carrier status for a functional
single nucleotide polymorphism in the IL-1β gene, which involves a
C–T transposition at position−511. Participants were genotyped to es-
tablishwhether theywere allele 2 (A2) carriers (genotype T/T or C/T) or
A1 non-carriers (genotype C/C). In the ﬁrst study, A2 carrier subjects
with schizophrenia had signiﬁcantly decreased total whitematter, fron-
tal gray matter, and temporal gray matter volumes compared with A2
carrier controls (Meisenzahl et al., 2001). The second study found signif-
icantly increased volumes of frontal white – but not gray – matter,
occipitalwhitematter, bilateral arcuate fasciculi and left inferior tempo-
ral gray matter in the A2 carrier schizophrenia subjects compared with
A1 non-carrier schizophrenia subjects. Graymatter volumes in the right
lateral prefrontal cortex, thalamus, insula and right medial temporal
lobe were signiﬁcantly lower among schizophrenia subjects compared
with controls. Gray andwhite matter volumes did not differ signiﬁcant-
ly between A2 versus A1 controls in any regions (Maitra et al., 2009). A
conventional DTI study found signiﬁcantly decreased FA in the superior
longitudinal, arcuate and uncinate fasciculi and forceps minor among
thosewith schizophrenia comparedwith controls. A signiﬁcant positive
correlation was also observed between serum concentrations of IL-6,but not C-reactive protein, and FA in the forceps minor among those
with schizophrenia (Prasad et al., 2013).
3.4. Astroglia
Eight neuropathological studies (230 subjects) yielded data on the
relationship between astroglial pathology and white matter (see
Table 4). One studymeasured astroglial density in the subgenual cingu-
late gray andwhitematter (the base, located at the depth of the sulcus—
and the crown), as well as the anterior corpus callosum. Astroglial den-
sity was signiﬁcantly decreased in subgenual cingulate gray matter
(speciﬁcally in layer I), both at the crown and the base of subgenual cin-
gulate white matter, and in anterior corpus callosum among those with
schizophrenia compared with controls (Williams et al., 2014). In a
follow-up analysis that was limited to the subgenual cingulate white
matter, the number of ﬁbrillary astroglia was signiﬁcantly decreased
at the base – but not the crown – among those with schizophrenia
(Williams et al., 2013a). Three additional studies reported that astroglial
density in white matter sections of the premotor area, the third ventri-
cle and the inferior horn subventricular zones, the dorsolateral prefron-
tal, superior temporal, and anterior cingulate cortices, and internal
capsule did not differ signiﬁcantly between subjects with schizophrenia
compared to controls. These three studies also found no signiﬁcant dif-
ferences in astroglial density in graymatter sections of subiculum, ento-
rhinal cortex, dorsolateral prefrontal cortex, superior temporal gyrus,
anterior cingulate cortex, thalamus, or putamen (Falkai et al., 1999;
Radewicz et al., 2000; Beasley and Hercher, 2011). Of these, two studies
also evaluated oligodendroglial density—one in the subgenual cingulate
gray andwhitematter aswell as the anterior corpus callosum (Williams
et al., 2014), and the other in the superﬁcial prefrontal white matter
Table 2
Association between microglial and white matter pathology in individuals with schizophrenia compared with controls.
Microglia-related outcome Schizophrenia Control Effect size (95% CI)a P valueb
Whole-brain
Doorduin et al., 2009 (w.m.) 11C-(R)-PK11195, mean (s.d.), BP 2.18 (0.70) 1.73 (0.51) 0.45 (−0.18 to 1.08) n/s
Doorduin et al., 2009 (g.m.) 11C-(R)-PK11195, mean (s.d.), BP 1.99 (0.64) 1.54 (0.41) 0.45 (−0.10 to 1.00) n/s
Left hemisphere
Pasternak et al., 2012 (w.m.) Free-water volume, mean 0.1145 (NR) 0.1031 (NR) 0.0115 (NR) b .02
Pasternak et al., 2012 (g.m.) Free-water volume, mean 0.1991 (NR) 0.1826 (NR) 0.0165 (NR) b .02
Right hemisphere
Pasternak et al., 2012 (w.m.) Free-water volume, mean 0.1154 (NR) 0.1042 (NR) 0.0112 (NR) b .02
Pasternak et al., 2012 (g.m.) Free-water volume, mean 0.2021 (NR) 0.1885 (NR) 0.0136 (NR) b .03
Prefrontal
Fillman et al., 2013 (w.m.) Density, mean (s.d.), cells mm−2 113 (4) 103 (4) 10 (8 to 12) b .03
Fillman et al., 2013 (g.m.) Density, mean (s.d.), cells mm−2 50 (NR) 49 (NR) – – n/s
Beasley and Hercher, 2013 (w.m.) Density, mean (s.d.), cells mm−2 NR (NR) NR (NR) – – n/s
Beasley and Hercher, 2013 (g.m.) Density, mean (s.d.), cells mm−2 NR (NR) NR (NR) – – n/s
Radewicz et al., 2000 (w.m.) c Density, mean (s.e.m.), cells mm−2 NR (NR) NR (NR) N26 – b .05
Radewicz et al., 2000 (g.m.) Density, mean (s.e.m.), cells mm−2 115 (9) 89 (5) 26 (19 to 33) b .05
Bayer et al., 1999 (both) Activation, n (%) 3 (21) 0 (0) 13 (1 to 267) .n/s
Hippocampus
Doorduin et al., 2009 (both) 11C-(R)-PK11195, mean (s.d.), BP 2.07 (0.42) 1.37 (0.30) 0.70 (0.33 to 1.07) .004
Superior temporal
Radewicz et al., 2000 (g.m.) c Density, mean (s.e.m.), cells mm−2 N139 (NR) NR (NR) N51 (NR) b .01
Radewicz et al., 2000 (g.m.) Density, mean (s.e.m.), cells mm−2 139 (6) 88 (5) 51 (46 to 56) b .01
Anterior cingulate
Radewicz et al., 2000 (w.m.)c Density, mean (s.e.m.), cells mm−2 NR (NR) NR (NR) N0 – –
Radewicz et al., 2000 (g.m.) d Density, mean (s.e.m.), cells mm−2 NR (NR) NR (NR) N0 – .n/s
BP, binding potential; (R)-[11C]-PK11195, isoquinoline (R)-N-11C-methyl-N-(1-methylpropyl)-1-(2-chlorophenyl)-isoquinoline-3-carboxamide; CI, conﬁdence interval; g.m., graymatter;
NR, not reported; n/s, not signiﬁcant; s.d., standard deviation; s.e.m., standard error of the mean w.m., white matter.
a Continuous data are mean difference (95% CI); categorical data are odds ratio (95% CI).
b Extracted from original reports.
c Values were inferred based on the following statement from the original report: “Although microglia were not quantiﬁed in the white matter, a qualitative comparison showed that
more HLA-DR immunoreactivity was observed in white matter than in grey matter.”
d Tissue fractional anisotropy was speciﬁcally decreased in the superior longitudinal fasciculus bilaterally, the right inferior frontal occipital fasciculus, and the intersection of callosal
ﬁbers with the right superior corona radiata. There were no signiﬁcant between-group differences in tissue fractional anisotropy in any gray matter regions in the brain.
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tween schizophrenia cases and controls in any of the brain regions
assessed (Beasley and Hercher, 2011; Williams et al., 2014). The previ-
ouslymentioned electronmicroscopy study also found swollen and vac-
uolated astroglia containing membranous myelin debris in both gray
and white matter of schizophrenia subjects but not controls (Uranova
et al., 2011).
One study compared the mRNA expression of nine astroglial
markers (diodinase type II, aquaporin-4, S100β, glutaminase, excitatory
amino acid transporter-2 [EAAT-2], thrombospondin, aldehyde dehy-
drogenase 1 family member L1 [ALDH1L1], glial ﬁbrillary acid protein
[GFAP] and vimentin) in post mortem specimens of anterior cingulate
gray andwhite matter. Expression of eachmarker in the anterior cingu-
late white matter or cortical layers I–III was not signiﬁcantly different
among those with schizophrenia compared to controls. However, the
expression of diodinase type II, aquaporin-4, S100β, glutaminase,
EAAT-2, and thrombospondin – but not ALDH1L1, GFAP, or vimentin –
was signiﬁcantly increased in layers IV-VI among those with schizo-
phrenia (Katsel et al., 2011). Another study used quantitative PCR to
measure astroglial (GFAP and ALDH1L1) and oligodendroglial (proteo-
glycan 4, platelet-derived growth factor receptorα, sex-determining re-
gion Y [SRY]-box 11, SRY-box 10, oligodendrocyte lineage transcription
factor 2, Fyn tyrosine kinase, transferrin, CNP, galactosylceramidase,
NKX6 homeobox 2 transcription factor, myelin-associated glycoprotein,
T-cell differentiation protein, myelin-oligodendrocyte glycoprotein,
myelin-associated oligodendrocyte basic protein and proteolipid pro-
tein) gene expression in post mortem specimens of thalamus, putamen
and corpus callosum. Expression of GFAP and ALDH1L1was signiﬁcant-
ly increased in all the brain regions assessed among those with schizo-
phrenia and major depressive disorder compared with those with
bipolar disorder and controls. Expression of CNP, galactosylceramidase,
myelin-associated glycoprotein and myelin-oligodendrocyte glycopro-
tein was signiﬁcantly decreased in all regions assessed among those
with schizophrenia compared with bipolar or major depressivedisorders and controls (Barley et al., 2009). Another study that evaluat-
ed GFAP protein concentration in the dorsal and ventral aspects of the
anterior limb of the internal capsule, found no signiﬁcant between-
group differences between subjects with schizophrenia relative to con-
trols (Beasley et al., 2009).
4. Discussion
To our knowledge, this is the ﬁrst systematic review on the relation-
ship between neuroinﬂammation and white matter pathology in
individuals with schizophrenia. There are several notable ﬁndings.
First, neuropathological and neuroimaging studies provide consistent
evidence of an association between schizophrenia andmicroglial activa-
tion and proliferation, particularly in the white matter. Neuropatholog-
ical studies that reported data onmicroglial density in graymatter alone
(not included in our review) have yielded mixed results (Arnold et al.,
1998; Falke et al., 2000; Wierzba-Bobrowicz et al., 2005; Steiner et al.,
2006, 2008; Busse et al., 2012). One free-water DTI study found an asso-
ciation between ﬁrst-episode schizophrenia and widespread neuroin-
ﬂammation and focally reduced FAT in frontal white matter. To our
knowledge, this is the only study of its kind, either in gray orwhitemat-
ter. Second, pro-inﬂammatory cytokine genetic mutations and mRNA
expression levels are associated with reduced white matter volume
and increased white matter neuronal density, respectively. Third,
astroglial density is decreased speciﬁcally in the subgenual cingulate
gray and white matter, and anterior corpus callosum in schizophrenia.
Studies not included in this reviewhave also reported reduced astroglial
density in anterior cingulate and dorsolateral prefrontal cortices, aswell
as hippocampus (Webster et al., 2001; Doyle and Deakin, 2002;
Rajkowska et al., 2002; Stark et al., 2004; Steffek et al., 2008). Since
astroglia regulate synaptic glutamate levels, these ﬁndings are con-
sistent with glutamatergic dysfunction that is associated with
schizophrenia (Najjar et al., 2013). Included studies provided incon-
sistent data on astroglial-marker gene and mRNA expression, and
Table 3
Association between cytokines and white matter pathology in individuals with schizophrenia compared with controls.
Outcome Cytokine-related ﬁndings P value
White matter
Whole-brain
Meisenzahl et al., 2001 White matter volume (IL-1β gene SNP) schizophrenia (A2) vs. controls (A1) .03
Meisenzahl et al., 2001 White matter volume – (IL-1β gene SNP) controls (A2) vs. controls (A1) .25
Occipital
Maitra et al., 2009 White matter volume (IL-1β gene SNP) schizophrenia (A2) vs. schizophrenia (A1) b .001
Prefrontal
Maitra et al., 2009 White matter volume (IL-1β gene SNP) schizophrenia (A2) vs. schizophrenia (A1) b .001
Maitra et al., 2009 White matter volume – (IL-1β gene SNP) controls (A2) vs. controls (A1) n/s
Orbitofrontal
Fung et al., 2014 Neuronal density (NeuN) (IL-6, IL-8, IL-1β, SERPINA3 mRNA) 43.7% schizophrenia (high) vs. controls .00000001
Fung et al., 2014 Neuronal density (NeuN) (IL-6, IL-8, IL-1β, SERPINA3 mRNA) 14.9% schizophrenia (low) vs. controls .00001
Fung et al., 2014 Neuronal density (NeuN) (IL-6, IL-8, IL-1β, SERPINA3 mRNA) 25.0% schizophrenia (high) vs. schizophrenia (low) .0007
Fung et al., 2014 Neuronal density (GAD65/67) (IL-6, IL-8, IL-1β, SERPINA3 mRNA) schizophrenia (high) vs. controls .007
Fung et al., 2014 Neuronal density (GAD65/67) (IL-6, IL-8, IL-1β, SERPINA3 mRNA) schizophrenia (low) vs. controls .005
Dorsolateral prefrontal
Fillman et al., 2013 Microglial density Correlation with IL-1βmRNA among schizophrenia, but not Controls .04
Fung et al., 2014 Neuronal density (NeuN) Correlation with GAD67 gray matter neuron density among Schizophrenia (high) (r = −0.54) .04
Fung et al., 2014 Neuronal density (NeuN) (IL-6, IL-8, IL-1β, SERPINA3 mRNA) 18.9% schizophrenia (high) vs. controls .06
Fung et al., 2014 Neuronal density (NeuN) – (IL-6, IL-8, IL-1β, SERPINA3 mRNA) schizophrenia (low) vs. controls n/s
Fung et al., 2014 Neuronal density (NeuN) – (IL-6, IL-8, IL-1β, SERPINA3 mRNA) schizophrenia (high) vs. schizophrenia (low) n/s
Fung et al., 2014 Neuronal density (GAD65/67) – (IL-6, IL-8, IL-1β, SERPINA3 mRNA) schizophrenia (high) vs. controls n/s
Fung et al., 2014 Neuronal density (GAD65/67) – (IL-6, IL-8, IL-1β, SERPINA3 mRNA) schizophrenia (low) vs. controls n/s
Arcuate fasciculi
Prasad et al., 2013 Fractional anisotropy – Correlation between IL-6 or CRP among schizophrenia n/s
Prasad et al., 2013 Fractional anisotropy Schizophrenia vs. controls .001
S. Longitudinal fasciculus
Prasad et al., 2013 Fractional anisotropy – Correlation in IL-6 or CRP among schizophrenia n/s
Prasad et al., 2013 Fractional anisotropy Schizophrenia vs. controls .001
Forceps minor
Prasad et al., 2013 Fractional anisotropy Correlation with IL-6 among schizophrenia (r = 0.49), but not controls .02
Prasad et al., 2013 Fractional anisotropy Schizophrenia vs. controls .03
Uncinate fasciculus
Prasad et al., 2013 Fractional anisotropy Correlation with IL-6, but not CRP, among schizophrenia (r = 0.37) .08
Prasad et al., 2013 Fractional anisotropy Schizophrenia vs. controls .04
Gray matter
Whole-brain
Meisenzahl et al., 2001 Gray matter volume – (IL-1β gene SNP) controls (A2) vs. controls (A1) n/s
Meisenzahl et al., 2001 Gray matter volume – (IL-1β gene SNP) schizophrenia (A2) vs. controls (A1) n/s
Temporal cortex
Meisenzahl et al., 2001 Gray matter volume (IL-1β gene SNP) schizophrenia (A2) vs. controls (A1) .04
Meisenzahl et al., 2001 Gray matter volume (IL-1β gene SNP) schizophrenia (A2) vs. schizophrenia (A1) .001
Meisenzahl et al., 2001 Gray matter volume – (IL-1β gene SNP) controls (A2) vs. controls (A1) n/s
Maitra et al., 2009 Gray matter volume (IL-1β gene SNP) schizophrenia (A2) vs. schizophrenia (A1) b .001
Maitra et al., 2009 Gray matter volume Schizophrenia vs. controls b .001
Thalamus, insula
Maitra et al., 2009 Gray matter volume Schizophrenia vs. controls b .001
Prefrontal cortex
Meisenzahl et al., 2001 Gray matter volume (IL-1β gene SNP) schizophrenia (A2) vs. controls (A1) b .02
Meisenzahl et al., 2001 Gray matter volume – (IL-1β gene SNP) controls (A2) vs. controls (A1) n/s
Maitra et al., 2009 Gray matter volume – (IL-1β gene SNP) controls (A2) vs. controls (A1) n/s
Maitra et al., 2009 Gray matter volume Schizophrenia vs. controls b .001
signiﬁcant decrease; , signiﬁcant increase;−, no signiﬁcant difference; A1, non-carrier (genotype C/C) for a functional single nucleotide polymorphism in the IL-1β gene that involves a
C–T transposition at position−511; A2, carrier (genotype T/T or C/T) for a functional single nucleotide polymorphism in the IL-1β gene that involves a C–T transposition at position−511;
CRP, C-reactive protein; DTI, diffusion-tensor imaging; GAD 65/67, glutamic acid decarboxylase 65 kDa and 67 kDa; MRI, magnetic resonance imaging; IL, interleukin; SERPINA3, serpin
peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 3; SNP, single nucleotide polymorphism.
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neurodegenerative disorders, included studies yielded consistent
evidence that astrogliosis is absent among individuals with schizo-
phrenia. Fourth, neither of the two studies having evaluated oligo-
dendroglial density in the subgenual cingulate gray and white
matter, anterior corpus callosum and prefrontal superﬁcial white
matter found signiﬁcant differences between subjects with schizo-
phrenia and controls. Since the anterior cingulate cortex and anterior
corpus callosum are critical for integrating limbic inputs and
connecting prefrontal cortices, respectively, these ﬁndings suggest
that factors in addition to oligodendroglial pathology contribute to
the disconnectivity of these structures associated with schizophre-
nia. Other studies not included in this review have reported reducedoligodendroglial density in the prefrontal region and superior frontal
gyrus (Uranova et al., 2002; Davis et al., 2003; Hof et al., 2003;
Uranova, 2004; Uranova et al., 2004; Vostrikov et al., 2004; Helldin
et al., 2007; Williams et al., 2013, 2014), but not in the anterior cin-
gulum bundle (Segal et al., 2009).
These ﬁndings should be interpreted in light of several limitations.
First, because the majority enrolled small numbers of patients and
sought small effect sizes, it is possible that some studies were inade-
quately powered and therefore yielding Type II errors. Second, differ-
ences in immunohistochemical techniques, selection criteria for cases,
predetermined anatomical regions of interests, and outcome measures
across studies, may have introduced measurement, reporting and/or
detection biases (Steiner et al., 2006; Schnieder and Dwork, 2011).
Table 4
Association between astroglial and white matter pathology in individuals with schizophrenia compared with controls.
Astroglia-related outcome Schizophrenia Control Effect size (95% CI)a P value b
White matter
3rd Ventricle subventricular zone
Falkai et al., 1999 [M] L Density, mean (s.d.), cells cm−3 160.7 (98.7) 147.8 (91.5) 12.90 (−58.84 to 84.64) n/s
Falkai et al., 1999 [F] L Density, mean (s.d.), cells cm−3 173.1 (91.5) 119.3 (84.5) 53.80 (−7.87 to 115.47) n/s
Falkai et al., 1999 [M] R Density, mean (s.d.), cells cm−3 157.9 (78.8) 155.4 (92.9) 2.50 (−62.72 to 67.72) n/s
Falkai et al., 1999 [F] R Density, mean (s.d.), cells cm−3 181.0 (104.6) 128.9 (101.5) 52.10 (−20.40 to 125.60) n/s
Premotor
Falkai et al., 1999 [M] L Density, mean (s.d.), cells cm−3 68.9 (53.5) 101.2 (49.6) −32.20 (−71.19 to 6.59) n/s
Falkai et al., 1999 [F] L Density, mean (s.d.), cells cm−3 47.9 (45.7) 75.0 (70.1) −27.10 (−70.39 to 16.19) n/s
Falkai et al., 1999 [M] R Density, mean (s.d.), cells cm−3 67.3 (46.5) 96.3 (63.4) −29.00 (−71.20 to 13.20) n/s
Falkai et al., 1999 [F] R Density, mean (s.d.), cells cm−3 42.6 (48.3) 59.5 (50.1) −16.90 (−51.73 to 17.93) n/s
Inferior horn subventricular zone
Falkai et al., 1999 [M] L Density, mean (s.d.), cells cm−3 106.8 (53.4) 172.9 (41.9) −66.10 (−99.20 to−33.00) b .0001
Falkai et al., 1999 [F] L Density, mean (s.d.), cells cm−3 138.5 (88.8) 115.4 (67.2) 23.10 (−36.10 to 82.24) n/s
Falkai et al., 1999 [M] R Density, mean (s.d.), cells cm−3 123.2 (50.4) 163.6 (43.5) −40.40 (−73.15 to−7.65) b .05
Falkai et al., 1999 [F] R Density, mean (s.d.), cells cm−3 135.4 (74.0) 121.4 (72.2) 14.00 (−41.16 to 69.16) n/s
Prefrontal or superior temporal
Beasley and Hercher, 2011 Density, mean (s.e.m.), cells mm−2 NR (NR) NR (NR) – – n/s
Radewicz et al., 2000 Density, mean (s.e.m.), cells mm−2 NR (NR) NR (NR) – – n/s
Radewicz et al., 2000 Density, mean (s.e.m.), cells mm−2 NR (NR) NR (NR) – – n/s
Thalamus
Barley et al., 2009 Gene expression: GFAP, ALDH1L1 NR (NR) NR (NR) – – b .05
Corpus callosum
Williams et al., 2013, 2014 Density, mean (s.d.), cells mm−2 12.5 (11.1) 31.6 (4.9) −19.10 (−26.44 to−11.76) b .05
Barley et al., 2009 Gene expression: GFAP, ALDH1L1 NR (NR) NR (NR) – – b .05
Internal capsule
Beasley et al., 2009 (dorsal) Protein concentration: GFAP 0.282 (0.081) 0.294 (0.036) −0.18 (−0.93 to 0.56) n/s
Beasley et al., 2009 (ventral) Protein concentration: GFAP 0.288 (0.089) 0.307 (0.057) −0.24 (−0.99 to 0.50) n/s
Barley et al., 2009 Gene expression: GFAP, ALDH1L1 NR (NR) NR (NR) – – b .05
Subgenual cingulate
Williams et al., 2013, 2014 base Density, mean (s.d.), cells mm−2 22.1 (3.0) 34.4 (4.0) −12.30 (−15.10 to−9.50) b .00001
Williams et al., 2013, 2014 crown Density, mean (s.d.), cells mm−2 21.4 (4.2) 31.8 (3.1) −10.40 (−13.47 to−7.33) b .00001
Anterior cingulate
Radewicz et al., 2000 Density, mean (s.d.), cells mm−2 NR (NR) NR (NR) – – n/s
Katsel et al., 2011 (mRNA) GFAP, ALDH1L1, GFAP, VIM, GS NR (NR) NR (NR) – – n/s
Katsel et al., 2011 (mRNA) DIO, AQP4, S100β, THBS4, EAAT2, GL NR (NR) NR (NR) – – n/s
Gray matter
Anterior cingulate
Radewicz et al., 2000 Density, mean (s.e.m.), cells mm−2 NR (NR) NR (NR) – – n/s
Katsel et al., 2011 (mRNA) GFAP, ALDH1L1, GFAP, VIM, GS NR (NR) NR (NR) – – n/s
Katsel et al., 2011 (mRNA) c DIO, AQP4, S100β, THBS4, EAAT2, GL NR (NR) NR (NR) −26% to−37% b .05
Prefrontal, superior temporal
Radewicz et al., 2000 Density, mean (s.e.m.), cells mm−2 NR (NR) NR (NR) – – n/s
Radewicz et al., 2000 Density, mean (s.e.m.), cells mm−2 NR (NR) NR (NR) – – n/s
Subiculum
Falkai et al., 1999 [M] L Density, mean (s.d.), cells cm−3 68.9 (60.9) 61.6 (36.1) 7.30 (−30.15 to 44.75) n/s
Falkai et al., 1999 [F] L Density, mean (s.d.), cells cm−3 65.8 (42.4) 46.7 (21.8) 19.10 (−3.35 to 41.55) n/s
Falkai et al., 1999 [M] R Density, mean (s.d.), cells cm−3 64.3 (57.9) 96.6 (94.6) −32.30 (−92.00 to 27.40) n/s
Falkai et al., 1999 [F] R Density, mean (s.d.), cells cm−3 70.4 (33.1) 49.9 (14.1) 20.50 (3.76 to 37.24) .05
Entorhinal
Falkai et al., 1999 [M] L Density, mean (s.d.), cells cm−3 66.1 (63.1) 53.1 (22.8) 13.00 (−22.30 to 48.30) n/s
Falkai et al., 1999 [F] L Density, mean (s.d.), cells cm−3 51.3 (31.9) 48.6 (19.5) 2.70 (−15.14 to 20.54) n/s
Falkai et al., 1999 [M] R Density, mean (s.d.), cells cm−3 60.4 (53.2) 69.5 (60.5) −9.10 (−49.77 to 31.57) n/s
Falkai et al., 1999 [F] R Density, mean (s.d.), cells cm−3 48.9 (27.9) 44.2 (19.3) 4.70 (−13.29 to 22.69) n/s
ALDH1L1, aldehyde dehydrogenase 1 family member L1; CI, conﬁdence interval; GFAP, glial ﬁbrillary acid protein; L, left; M, males; n/s, not signiﬁcant; F, females; R, right; s.d., standard;
s.e.m., standard error of the mean.
a Effect sizes were calculate as unstandardized mean differences with the exception of the values for Beasley et al., 2009 which were standardized mean differences.
b Values were extracted from the original reports.
c Values for this row speciﬁcally refer to layers IV–VI, as there was no between-group difference in layers I–III for these genes.
108 S. Najjar, D.M. Pearlman / Schizophrenia Research 161 (2015) 102–112Third, since microglial activation can be inﬂuenced by the severity of
disease (Rogers et al., 1988;Mattiace et al., 1990) and attenuated by an-
tipsychotics (Kato et al., 2011a,b), and themajority of subjects in neuro-
pathological studies had chronic schizophrenia, neuroinﬂammatory
changes may have been under-reported (Steiner et al., 2006; Fillman
et al., 2013).
Whether neuroinﬂammation is a cause or effect of white matter
pathology in schizophrenia remains unclear. Several observations
favor a causative role. While the initial white matter inﬂammatory re-
sponse may be evoked by antecedent degenerative and destructive
changes of whitematter, several animal models of perinatal whitemat-
ter injury have consistently showed that microglial activation-relatedinﬂammatory changes (e.g., proinﬂammatory cytokines, inducible nitric
oxide synthase, reactive oxygen species) are principally responsible
for pre-oligodendroglial apoptotic death, leading to impairment of
myelination and limitation of normal development of white matter
(Haynes et al., 2003; Pang et al., 2003; Matute et al., 2007; Pang et al.,
2010; Taylor et al., 2010). Our ﬁndings of microglial activation, in-
creased neural IL-6 and IL-1β levels (particularly in white matter) and
a negative correlation between serum IL-6 concentrations and FA values
in the uncinate fasciculus among those with schizophrenia are consis-
tent with this interpretation. Themost recentmeta-analysis of cytokine
alterations in schizophrenia, reported increased IL-6 and IL-1β levels
among those with schizophrenia (Miller et al., 2011). Experimental
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dendroglial death, myelin damage and axonal damage in vitro (di Penta
et al., 2013), whereas administration of IL-1 receptor antagonist can im-
provemyelination of injuredwhitematter (Pang et al., 2003). One study
included in our review reported an inverse relationship between IL-6
and brain-derived neurotropic factor (BDNF) levels among the sub-
group of schizophrenia subjects exhibiting high mRNA expression of
IL-6 and IL-1β (Fillman et al., 2013). Experimental models have shown
an inverse relationship between IL-1β and BDNF levels (Barrientos
et al., 2004) and that lowBDNF concentrations canworsenwhitematter
injury (Cui et al., 2013). In addition, our included study's ﬁnding of an
association between ﬁrst-episode schizophrenia and diffusely increased
extracellular free-water volume with focally decreased FAT in frontal
white matter, suggests that neuroinﬂammation precedes myelin break-
down and axonal degeneration in schizophrenia (Pasternak et al.,
2012). Several additional neuroimaging studies not included in our re-
view provide indirect evidence associating neuroinﬂammation with
white matter pathology in schizophrenia (Pfefferbaum et al., 1999;
DeLisi et al., 2006; Garver et al., 2008; Peters et al., 2010).
Major risk factors for schizophrenia include a history of maternal
and prenatal infections, prior hospitalization for severe infection, and
autoimmune comorbidity (Yolken and Torrey, 1995; Gilvarry et al.,
1996; Torrey et al., 1997; Buka et al., 2001; Brown et al., 2005; Eaton
et al., 2006; Mortensen et al., 2007; Torrey et al., 2007; Buka et al.,
2008; Brown and Derkits, 2010; Benros et al., 2011; Chen et al., 2012;
Benros et al., 2014a,b)—all of which link elevated pro-inﬂammatory cy-
tokines to the pathogenesis schizophrenia (as reviewed by Miller et al.
(2013a) and Meyer (2013)). Prenatal exposure to inﬂammation or in-
fection can injure developing oligodendroglia, resulting in prominent
white matter pathology and motor, cognitive, and behavioral impair-
ments (recently reviewed by Deng (2010))—all of which are associated
with pre-psychosis and schizophrenia (Chew et al., 2013). A signiﬁcant
positive correlation has been observed between fetal exposure to ele-
vated maternal serum IL-8 levels during second and third trimesters
and increased ventricular cerebrospinal ﬂuid volume, as well as de-
creased left entorhinal and posterior cingulate cortical volumes in
schizophrenia (Ellman et al., 2010). These studies support the hypothe-
sis that prenatal inﬂammation-induced microglial priming is involved
in the pathophysiology of schizophrenia (Meyer, 2013).
An increased density of interstitial white matter neurons, one of the
more consistent pathological abnormalities found in schizophrenia
(Anderson et al., 1996; Eastwood and Harrison, 2003; Kirkpatrick
et al., 2003; Eastwood and Harrison, 2005; Connor et al., 2011; Yang
et al., 2011) (recently reviewed by Connor et al. (2011)), further sup-
ports the hypothesis that neuroinﬂammation precedes white matter
pathology in schizophrenia. One putative mechanism of increased
white matter neuronal density in human disease involves entrapment
of neurons migrating from the germinal matrix to the cortex due to
inﬂammation-induced early white matter injury (Rousset et al., 2006;
Leviton and Gressens, 2007). IL-6 has been shown to directly inhibit
neuronal migration in vitro (Wei et al., 2011). Another putative mecha-
nism involves inﬂammation-induced aberrant differentiation of glial
cells into neurons (Leviton and Gressens, 2007; Connor et al., 2011).
Cultured microglia have been shown to express neuronal markers fol-
lowing exposure to interferon-γ (Butovsky et al., 2007).
Several ﬁndings from our review suggest that thesemechanisms are
relevant to schizophrenia. The density of NeuN-immunoreactive white
matter neurons was (a) increased in the orbitofrontal region among
those with schizophrenia; (b) increased in the orbitofrontal and
dorsolateral prefrontal regions in high-inﬂammation versus low-
inﬂammation schizophrenia subgroups; and (c) negatively correlated
with GAD67-immunoreactive dorsolateral prefrontal gray matter neu-
rons in the high-inﬂammation subgroup only. The latter ﬁnding is consis-
tentwithmanyneuropathological studies that have documented reduced
expression of GAD67 in the dorsolateral prefrontal graymatter in individ-
uals with schizophrenia (Guidotti et al., 2000; Hashimoto et al., 2008;Thompson et al., 2009). However, the lack of a difference in the density
of GAD67-immunoreactive orbitofrontal white matter neurons between
high-inﬂammation versus low-inﬂammation subgroups suggests that
factors in addition to inﬂammation, such as persistent cortical subplate
remnants (Connor et al., 2011) may also play a role (Fung et al., 2014).
In conclusion, neuroinﬂammation is associated with white matter
pathology characterized by axonal degeneration, myelin breakdown,
reduced density of astroglia and oligodendroglia in selected areas and
increased density of white matter neurons among individuals with
schizophrenia. Neuroinﬂammation may contribute to white matter
structural and functional disconnectivity, even at the ﬁrst episode of
psychosis. Adequately powered neuropathological studies, weighted
towards younger individuals who died shortly after ﬁrst psychotic
episodes, are needed to further explore the relationship between neuro-
inﬂammation and early white matter pathology in schizophrenia.
Controlled longitudinal studies using free-water DTI analyses in individ-
uals with ﬁrst-episode schizophrenia before and after treatment with
immune or anti-inﬂammatory therapies are also likely to be informa-
tive. Clinical trials evaluating the effect of early initiation of existing
and novel immune and anti-inﬂammatory therapies on white matter
pathology and disease progression in schizophrenia are warranted.
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